Effect of Dupilumab on Onset of Type 1 Disease
Study Dates
Last Modified
Tags
Publisher
Abstract
Study to determine whether use of the Type 2 blocker dupilumab in children with atopic dermatitis and asthma is associated with increased frequency of developing Type 1 disease.
Affiliation(s)
Funder(s)
Provenance
Description
This study investigates whether dupilumab, a Type 2 inflammation-blocking agent commonly used to treat allergic diseases, is associated with an increased risk of developing Type 1 diseases in children. Using the PEDSnet electronic health record network, researchers conducted a multicenter retrospective cohort study involving children aged 6-17 with asthma and/or atopic dermatitis, comparing those treated with dupilumab to those untreated and non-atopic children. The primary outcome was the diagnosis of Type 1 diseases, including conditions affecting the skin, endocrine, gastrointestinal, and other systems.
The results showed that while overall rates of Type 1 disease diagnoses were low, dupilumab-treated children had a 1.9 times higher risk of developing Type 1 diseases within 4 years of treatment. Despite this increased risk, the findings suggest the need for further prospective studies to confirm the accuracy of these diagnoses and better understand the long-term side effects of dupilumab.
Cohort Description
Study sample consisted of three cohorts:
- Children with atopic dermatitis and/or persistent asthma who have received therapy with dupilumab for at least 3 months.
- A control population of children with atopic dermatitis and/or persistent asthma who are not treated with dupilumab.
- A non-atopic control population of children without atopic dermatitis, asthma, or other atopic diseases who are not treated with dupilumab.
Development Code
Vocabulary
Clinical Subjects
Related Publications
Creative Commons license
